Clinical trial · Interventional
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
NCT02424955CI-TRIAL-00067901completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Liver Carcinoma | Liver Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Tumor | Liver Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3D ultrasound | Diagnostic Test | — | UNRESOLVED |
| perflutren lipid microspheres | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 3D Perfusion Ultrasound
- description
- undergo 3D ultrasound perfusion imaging with perflutren
- interventionNames
- Drug: perflutren lipid microspheres
- Diagnostic Test: 3D ultrasound
Primary outcomes (3)
- measure
- Changes in Blood Perfusion (Blood Volume)
- timeFrame
- Baseline (pre-treatment), 0-7 days post treatment, 2-4 months post treatment.
- description
- The purpose of this pilot project is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
- measure
- Changes in Blood Perfusion (Mean Flow Velocity)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to understand and willingness to sign the written informed consent document * Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative Radiotherapy (SABR) * Patient is at least 18 years of age. No gender/race-ethnic restrictions. * Performance status (ECOG) between 0-3 * History and Physical done within 4 weeks of enrollment. Exclusion Criteria: * Patient has previously been enrolled in and completed this study. * Known right to left cardiac shunt, bidirectional or transient. * Patient has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations. * History of hypersensitivity to the contrast agent perflutren * History of pulmonary hypertension * Patients who are pregnant or are trying to become pregnant
References
Publications (0)
Data not yet available
No reference posted for this study.